Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | HTR2B | P41595 | 2/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25600476 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2ACHEKMT2APOLBKDM4E | |
| SCHEMBL25600474 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2ACHEKMT2APOLBKDM4E | |
| SCHEMBL26295541 | 0.94 | SMN1; SMN2 (0.39) | SMN1; SMN2ACHEKMT2AKDM4EALDH1A1 | |
| SCHEMBL25600513 | 0.89 | POLB (0.44) | SMN1; SMN2KMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL25630718 | 0.87 | ACHE (0.49) | SMN1; SMN2ACHEKMT2APOLBKDM4E | |
| SCHEMBL25605397 | 0.87 | SMN1; SMN2 (0.39) | SMN1; SMN2ACHEKMT2APOLBKDM4E | |
| SCHEMBL25605411 | 0.86 | SMN1; SMN2 (0.43) | SMN1; SMN2ACHEKMT2APOLBKDM4E | |
| SCHEMBL25605407 | 0.86 | SMN1; SMN2 (0.43) | SMN1; SMN2ACHEKMT2APOLBKDM4E | |
| SCHEMBL25630719 | 0.86 | SMN1; SMN2 (0.43) | SMN1; SMN2ACHEKMT2APOLBKDM4E | |
| SCHEMBL19264191 | 0.84 | SMN1; SMN2 (0.53) | SMN1; SMN2KDM4EALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | SMN1; SMN2 716/4885ACHE 2091/4885KMT2A 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.